ciprofibrate has been researched along with Hypercholesterolemia in 12 studies
Hypercholesterolemia: A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ciprofibrate is a hypolipidaemic compound that acts primarily by enhancing the oxidation of fatty acids in the liver and, consequently, decreasing the production of hepatic VLDL." | 1.32 | The peroxisome-proliferator-activated receptor alpha agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E. ( Borensztajn, J; Fu, T; Kashireddy, P, 2003) |
| "Ciprofibrate treatment (100 mg/day for 1 month) effected marked reductions in both total plasma LDL and apo B-100 levels (approximately 19% and approximately 23%, respectively)." | 1.29 | Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia. ( Bruckert, E; Chapman, MJ; Dejager, S, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 8 (66.67) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, T | 2 |
| Kashireddy, P | 1 |
| Borensztajn, J | 2 |
| Kozarsky, KF | 1 |
| Okopień, B | 1 |
| Krysiak, R | 1 |
| Kowalski, J | 1 |
| Madej, A | 1 |
| Belowski, D | 1 |
| Zieliński, M | 1 |
| Herman, ZS | 1 |
| Devuyst, O | 2 |
| Goffin, E | 2 |
| Pirson, Y | 2 |
| van Ypersele de Strihou, C | 2 |
| Bruckert, E | 1 |
| Dejager, S | 1 |
| Chapman, MJ | 1 |
| Shepherd, J | 1 |
| Muls, E | 1 |
| Van Gaal, L | 1 |
| Autier, P | 1 |
| Vansant, G | 1 |
| Perault, MC | 1 |
| Fievre, JL | 1 |
| Dejean, C | 1 |
| Martin, A | 1 |
| Vandel, B | 1 |
| Zimetbaum, P | 1 |
| Frishman, WH | 1 |
| Kahn, S | 1 |
| Michel, G | 1 |
| Bouckaert, A | 1 |
| Simpson, IA | 1 |
| Lorimer, AR | 1 |
| Walker, ID | 1 |
| Davidson, JF | 1 |
2 reviews available for ciprofibrate and Hypercholesterolemia
| Article | Year |
|---|---|
Mechanism of action of fibrates.
Topics: Apolipoproteins B; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Huma | 1993 |
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type 2; Fenofibrate; Fibric Acids; | 1991 |
2 trials available for ciprofibrate and Hypercholesterolemia
| Article | Year |
|---|---|
Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates.
Topics: Adult; Anticholesteremic Agents; C-Reactive Protein; Clofibric Acid; Cytokines; Diabetes Mellitus, T | 2005 |
[An epidemiological study of hypercholesterolemia in the Grand Duchy of Luxembourg].
Topics: Adult; Aged; Cholesterol, LDL; Cholesterol, VLDL; Clofibric Acid; Epidemiologic Methods; Female; Fib | 1990 |
8 other studies available for ciprofibrate and Hypercholesterolemia
| Article | Year |
|---|---|
The peroxisome-proliferator-activated receptor alpha agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E.
Topics: Animals; Apolipoproteins; Arteriosclerosis; Blotting, Northern; Blotting, Western; Clofibric Acid; F | 2003 |
Overexpression of SR-BI by adenoviral vector reverses the fibrateinduced hypercholesterolemia of apolipoprotein E-deficient mice.
Topics: Adenoviridae; Animals; Apolipoproteins E; CD36 Antigens; CHO Cells; Cholesterol; Clofibric Acid; Cri | 2003 |
Hypercholesterolemia treatment in a renal transplant patient.
Topics: Anticholesteremic Agents; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Humans; Hy | 1994 |
Creatinine rise after fibrate therapy in renal graft recipients.
Topics: Bezafibrate; Clofibric Acid; Creatinine; Female; Fenofibrate; Fibric Acids; Humans; Hypercholesterol | 1993 |
Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia.
Topics: Adult; Apolipoprotein B-100; Apolipoproteins B; Clofibric Acid; Fibric Acids; Humans; Hypercholester | 1993 |
Effects of initial BMI and on-treatment weight change on the lipid-lowering efficacy of fibrates.
Topics: Body Mass Index; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholes | 1997 |
[Cytolytic hepatic damage caused by ciprofibrate].
Topics: Aged; Chemical and Drug Induced Liver Injury; Clofibric Acid; Female; Fibric Acids; Humans; Hypercho | 1992 |
Effect of Ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolaemia.
Topics: Adult; Alkaline Phosphatase; Cholesterol; Clofibrate; Clofibric Acid; Fibric Acids; Fibrinogen; Fibr | 1985 |